Yang Yun, Tang Tian, Peng Wei, Xia Lin, Wang Xiaodong, Duan Baofeng, Shu Ye
Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.
Department of Hepatic Surgery and Hepatic Transplantation Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan Province, China.
J Surg Res. 2015 Feb;193(2):764-71. doi: 10.1016/j.jss.2014.08.040. Epub 2014 Aug 27.
Recently identified class of microRNAs (miRNAs) provided a new insight in cancer research. As a member of miRNAs family, miR-155 expression demonstrated the correlation with tumor stage. Thus, its expression level can be potentially used for staging rectal tumors. The aim of this study was to systematically evaluate the potential abilities of miR-155 in preoperatively N staging.
Expression of miR-155 was detected and quantitated in rectal cancer tissues and in adjacent nonmalignant tissues from 40 patients by TaqMan MicroRNA assays. Preoperative enhanced computed tomography (CT) scan, serum amyloid A protein (SAA), carcinoembryonic antigen (CEA), and postoperative pathologic biopsy were performed.
A significant overexpression of miR-155 was observed in rectal carcinoma tissues (0.137 ± 0.095 versus 0.093 ± 0.091, P = 0.043). High expression of miR-155 in N1-2 (0.09 ± 0.038 versus 0.183 ± 0.111, P = 0.001) and III and IV stages (0.091 ± 0.039 versus 0.178 ± 0.111, P = 0.002) presented its potential correlation with N and tumor-node-metastasis combined stages. Receiver operating characteristics curve analysis showed that miR-155 could discriminate N0 from N1-2 with 85.0% sensitivity and 85.0% specificity at the cutoff value of 0.125. miR-155 and CT had nearly equal performances in sensitivity (0.850 versus 0.700, P = 0.450) and specificity (0.850 versus 0.550, P = 0.077) in predicting N1-2 stage. Compared with CT + SAA, miR-155 had similar sensitivity (0.850 versus 0.950, P = 0.617) but higher specificity (0.750 versus 0.200, P = 0.015) for lymph node assessment.
Increase in the expression of miR-155 might represent a potential valuable marker for rectal carcinoma N and combined tumor-node-metastasis staging.
最近发现的一类微小RNA（miRNA）为癌症研究提供了新的见解。作为miRNA家族的成员，miR-155的表达与肿瘤分期相关。因此，其表达水平有可能用于直肠癌的分期。本研究的目的是系统评估miR-155在术前N分期中的潜在能力。
采用TaqMan MicroRNA检测法对40例患者的直肠癌组织及癌旁非癌组织中miR-155的表达进行检测和定量分析。术前行增强计算机断层扫描（CT）、血清淀粉样蛋白A（SAA）、癌胚抗原（CEA）检测，并进行术后病理活检。
直肠癌组织中miR-155显著高表达（0.137±0.095对0.093±0.091，P = 0.043）。miR-155在N1-2期（0.09±0.038对0.183±0.111，P = 0.001）以及Ⅲ期和Ⅳ期（0.091±0.039对0.178±0.111，P = 0.002）的高表达提示其与N分期及肿瘤-淋巴结-转移综合分期可能相关。受试者工作特征曲线分析显示，miR-155在截断值为0.125时，区分N0与N1-2的灵敏度为85.0%，特异度为85.0%。在预测N1-2期方面，miR-155与CT的灵敏度（0.850对0.700，P = 0.450）和特异度（0.850对0.550，P = 0.077）相近。与CT+SAA相比，miR-155在评估淋巴结方面具有相似的灵敏度（0.850对0.950，P = 0.617），但特异度更高（0.750对0.200，P = 0.015）。
miR-155表达增加可能是直肠癌N分期及肿瘤-淋巴结-转移综合分期的潜在有价值标志物。
Zotero 插件